How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?  

We have limited data for cross-study comparison of pirtobrutinib versus venetoclax. In the BRUIN trial, in patients who were cBTKi-exposed and BCL2i-naïve (n=154), the ORR was 83%, the median PFS was 23 months, and the 1-year and 2-year OS were 90% and 83%, respectively (Woyach et al., ASH 2023...

BRUIN trial enrolled patients with a median of 3 prior lines of treatment. The response rate with pirtobrutinib is close to 80%. However, overall PFS is about 1.5-2 years. So, most patients will eventually relapse after pirtobrutinib.It is possible that the use of pirtobrutinib in earlier lines of t...